All In Biotech

Drug Trial Radar · NCT07789483

An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,180

Planned (sponsor's estimate)

Start

Nov 23, 2027

Primary completion

Jul 11, 2030

Study completion Jul 11, 2030

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated with ALXN2220 in addition to SoC who have completed Study ALXN2220-ATTRCM-301.

Conditions

  • Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Interventions

  • ALXN2220Drug

    To be administered as an IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with TEAEsTime frame: Up to 24 months

Locations

195 sites in 27 countries. Site status is shown where the registry gives one.

  • Research Site

    Irvine, California

  • Research Site

    La Jolla, California

  • Research Site

    Palo Alto, California

  • Research Site

    San Francisco, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Jacksonville, Florida

  • Research Site

    Weston, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Boston, Massachusetts

  • Research Site

    Boston, Massachusetts

  • Research Site

    Kansas City, Missouri

  • Research Site

    St Louis, Missouri

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Stony Brook, New York

  • Research Site

    Chapel Hill, North Carolina

  • Research Site

    Durham, North Carolina

  • Research Site

    Cleveland, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Danville, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Charleston, South Carolina

  • Research Site

    Greenville, South Carolina

  • Research Site

    Memphis, Tennessee

  • Research Site

    Fort Worth, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Falls Church, Virginia

  • Research Site

    Richmond, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Madison, Wisconsin

  • Research Site

    Ciudad de Buenos Aires, Argentina

  • Research Site

    Buenos Aires, Buenos Aires, Argentina

  • Research Site

    CABA, Buenos Aires, Argentina

  • Research Site

    Ciudad de Buenos Aires, Buenos Aires F.D., Argentina

  • Research Site

    Córdoba, Córdoba Province, Argentina

Showing 40 of 195 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.